Skip to content
EmergingResearch compoundLimited evidence

PRL‑8‑53

Experimental nootropic from the 1970s: only one human memory study has been done.

NootropicMemoryCholinergicAcetylcholineDopamine
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassMemory · Cholinergic
Primary targetCholinergic signaling
Targets3 receptor targets
EvidenceLimited evidence
Affected systemsAcetylcholineDopamine

Contents

DETAILED OVERVIEW

What is PRL-8-53?

PRL-8-53 is an experimental compound that was patented in the 1970s to improve memory. It is not approved as a medicine anywhere, it is sold as a research chemical, and in the United Kingdom it is banned by law. Only one human study has been done, a placebo-controlled trial in 1978: in it, the participants' verbal memory improved, more strongly in older people and in those who performed poorly at the start.

It presumably affects the messengers acetylcholine and dopamine, but its exact mechanism is still unknown. No follow-up study has been done since, so the data are very thin and its long-term safety is unknown. It can cause anxiety, restlessness, insomnia and tremor, and according to the patent description also seizures; it is best avoided in epilepsy, and there is no safety data for pregnancy or breastfeeding.

Mechanism

Cholinergic + dopaminergic modulation

Half-life

No published human data

Legal status

Investigational, not approved

Receptor profile

  • Cholinergic signalingModerate
  • Dopamine D2 receptorModerate
  • Serotonin 5-HT2 receptorWeak

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Anxiety and restlessness reported at higher doses
  • Insomnia and disturbed sleep (cholinergic-dopaminergic stimulation)
  • Tremor and shakiness at higher doses
  • Mild sweating in some users
  • Risk of convulsive, seizure-type activity at high doses (per patent)
  • Highly variable individual response, unpredictable effect profile
  • Unknown long-term safety, no follow-up human data

Contraindications · 6

  • Avoid during pregnancy and breastfeeding (no safety data)
  • Avoid with seizure disorders or epilepsy (potential to lower seizure threshold)
  • Caution with anxiety disorders or sleep disturbance
  • Increased risk when combined with other dopaminergic or cholinergic agents
  • Unapproved experimental compound sold as an uncontrolled research chemical, avoid high doses
  • Limited human data, consider only cautiously at low doses under supervision

Related Nootropics

Same therapeutic category

FAQ

FAQ

PRL-8-53 is an older experimental compound, patented back in the 1970s, developed with the goal of improving memory. Only a single 1978 double-blind, placebo-controlled human trial ever studied it, and that trial makes up nearly everything we know about it. So while it's an interesting historical and research candidate in the memory space, there is still barely any reliable, repeated human evidence for how well it actually works.

Telegram

Have a question about PRL‑8‑53?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC18H21NO2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.